Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nemalan Selvaraj

Interventional Cardiology Fort Myers, FL Doctor of Osteopathy

NPI 1821350539 CMS profile 174168

13340 Metro Parkway, Suite 200, Fort Myers, FL 33966

Open in the dashboard

General payments

$1,799

69 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nemalan Selvaraj of Fort Myers, FL is reported in the CMS Open Payments database as having received $1,799 across 69 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 18th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $693 25
2024 General $251 9
2023 General $322 10
2022 General $50 3
2021 General $128 7
2020 General $26 2
2019 General $328 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nemalan Selvaraj
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Nemalan Selvaraj were reported at $693. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Nemalan Selvaraj Interventional Cardiology median Middle half National median
2019 $328 $1,097 $329–$3,048 $163
2020 $26 $473 $161–$1,480 $114
2021 $128 $677 $233–$1,827 $132
2022 $50 $978 $333–$2,724 $149
2023 $322 $1,136 $382–$2,986 $160
2024 $251 $1,181 $395–$3,326 $164
2025 $693 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Shockwave Medical, Inc $404 11 payments
  2. Abiomed $393 10 payments
  3. Kestra Medical Technology Services, Inc. $146 1 payment
  4. Abbott Laboratories $142 7 payments
  5. Chiesi USA, Inc. $136 7 payments
  6. Boston Scientific Corporation $135 6 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $77 6 payments
  8. Novartis Pharmaceuticals Corporation $57 3 payments
  9. Terumo Medical Corporation $48 2 payments
  10. Cardiovascular Systems Inc. $39 3 payments
  11. Other $221 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,799 69 payments
Products named General payments · program years 2019–2025
  1. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $380 10 payments
  2. Impella $257 6 payments
  3. Assure WCD $146 1 payment
  4. KENGREAL $114 6 payments
  5. LifeVest $77 6 payments
  6. ENTRESTO $57 3 payments
  7. ANGIO-SEAL $48 2 payments
  8. TR BAND $48 2 payments
  9. Confirm Rx $41 2 payments
  10. RESONATE $39 1 payment
  11. Other $507 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,039

Median for Interventional Cardiology: 2,236

Drug cost

$296,710

Median for Interventional Cardiology: $380,412

Branded share of claims

33.1%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 130 $164,827
Repatha Sureclick Evolocumab Brand 67 $70,322
Xarelto Rivaroxaban Brand 22 $37,772
Praluent Pen Alirocumab Brand 14 $11,369
Ranolazine Er Ranolazine Brand 34 $2,758
Metoprolol Succinate Generic 100 $1,994
Atorvastatin Calcium Generic 129 $1,113
Ezetimibe Generic 42 $940
Clopidogrel Clopidogrel Bisulfate Brand 62 $760
Prasugrel Hcl Generic 20 $660

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$145,706

Medicare's payments for the services billed

Medicare patients

795

Average age 78

Services billed

1,926

370 women, 425 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 72%
Arthritis 59%
Heart failure 52%
Atrial fibrillation 52%
Diabetes 43%
Chronic kidney disease 43%
COPD 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record